1. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
- Author
-
Gizeh Pérez-Tenorio and Olle Stål
- Subjects
Adult ,Cancer Research ,Antineoplastic Agents, Hormonal ,Receptor, ErbB-2 ,Neuregulin-1 ,Breast Neoplasms ,Protein Serine-Threonine Kinases ,Disease-Free Survival ,Receptor tyrosine kinase ,S Phase ,Immunoenzyme Techniques ,heregulin β1 ,breast cancer ,Breast cancer ,Proto-Oncogene Proteins ,medicine ,Humans ,PKB ,Survival rate ,Protein kinase B ,Survival analysis ,erbB-2 ,biology ,Akt ,Molecular and Cellular Pathology ,Cancer ,DNA, Neoplasm ,Middle Aged ,Flow Cytometry ,Prognosis ,Antiestrogen ,medicine.disease ,Survival Rate ,Tamoxifen ,Treatment Outcome ,Proto-Oncogene Proteins c-bcl-2 ,Oncology ,Goserelin ,biology.protein ,Cancer research ,endocrine treatment ,Female ,Proto-Oncogene Proteins c-akt ,medicine.drug - Abstract
Akt/PKB is a serine/threonine protein kinase that regulates cell cycle progression, apoptosis and growth factor mediated cell survival in association with tyrosine kinase receptors. The protein is a downstream effector of erbB-2 with implications in breast cancer progression and drug resistance in vitro. We aimed to examine the role of Akt-1 in breast cancer patients, by determining whether the expression (Akt-1) and/or activation (pAkt) were related to prognostic markers and survival. The expression of erbB-2, heregulin β1 and Bcl-2 was also assessed by flow cytometry or immunohistochemistry. This study comprised 93 patients, aged
- Published
- 2002
- Full Text
- View/download PDF